Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic

    - Major Threat Treatable With StatC(TM); FDA-Approved Drugs to Begin
    Testing in U.S. Animal Models

    LOS ANGELES and GUANGZHOU, China, Aug. 12 /CNW/ - An internationally
renowned avian influenza expert today hailed "encouraging and exciting"
results from experiments conducted by his research team. This study
demonstrated impressive efficacy of a novel statin/caffeine combination, 
StatC(TM) in the treatment and prevention of H5N1, H1N1 and H3N2 in a mouse

    To view the Multimedia News Release, please click:

    Dr. Jiahai Lu, from the School of Public Health, Sun Yat-sen University
in Guangzhou, China, has published extensively in the field of avian
influenza, and has been researching the breakthrough compound StatC(TM) for
the past two years on behalf of Canopus Biopharma (OTCPK:CBIA), a US
corporation who discovered and patented the potential of this antiviral
    "The global distribution of the highly pathogenic H5N1 avian influenza
has caused the World Health Organization to show its profound concern
regarding the possibility of the virus spreading from human to human in the
future," stated Dr. Lu. "Furthermore, the development of resistance to two
approved anti-influenza drugs, oseltamivir (Tamiflu(R)) and zanamivir
(Relenza(R)), as well as the lack of adequate vaccines has increased the need
of developing new antiviral drugs."
    "Consequently, I am delighted to be involved in the preclinical research
stage of this innovative antiviral candidate, and look forward to continuing
our successful collaboration with Canopus Biopharma in this area."
    Dr. Lu and his colleagues have conducted extensive animal studies with
StatC(TM) against three influenza strains, H5N1 (avian influenza, bird flu),
H1N1 (Spanish influenza) and H3N2 (Hong Kong influenza). StatC(TM) is a
combination of two FDA approved compounds which have been re-formulated by
Canopus BioPharma for the prevention and treatment of Influenza. Oseltamivir
and ribavirin were used as positive controls in this study. In the H5N1 model,
StatC(TM) prevented and relieved the symptoms of H5N1 infection, inhibited
lung damage and H5N1 virus replication in the lungs of mice, and was as
effective as oseltamivir in both prevention and therapy models. There were no
animals with positive viral detection in the groups nasally administered with
StatC(TM). Likewise, StatC(TM) demonstrated similar results against the H3N2
and H1N1 viruses.
    "We are encouraged with these findings," said Dr. Lu. "It is possible
that higher doses of statin than those used in this study may result in even
greater efficacy. StatC(TM) also appeared to be more effective when
administered preventatively." With current positive results, Canopus BioPharma
is looking to form a co-development agreement or licensing arrangements with
pharmaceutical companies and Government health authorities interested in
providing more economical and universal treatment for their populations in the
event of a pandemic.
    At the forefront of influenza research in Guangzhou, China, Dr. Lu is
perfectly placed to further investigate the synergistic properties of the
statin/caffeine combination. "We are also motivated at the potential of this
compound in comparison with other currently available anti-influenza
medications. It's clear that there is significant global need for a superior,
low cost and plentiful alternative in the fight against influenza," added
Dr. Lu. While StatC(TM) has proven to be highly efficacious against the most
virulent strains of influenza, it must be noted that StatC(TM) is also
extremely effective against non-fatal, human forms of the virus that occur
    Approved by the Food and Drug Administration, oseltamivir (Tamiflu(R)) is
the leading prescription medicine approved for the prevention and treatment of
influenza in adults and children. Datamonitor, the world's leading provider of
online data, analytic and forecasting platforms for key vertical sectors,
forecasts that global market demand for influenza treatments will expand to
370 million doses and a market value of approximately $3.7 billion by 2010.
    Canopus BioPharma's strategy for developing StatC(TM) includes continued
animal testing in partnership with its extensive network of American and
Chinese based research laboratories. The next step involves a ferret animal
model using a lethal strain of influenza to examine the efficacy of StatC(TM).
Once completed, Canopus BioPharma's preclinical results will then satisfy the
FDA's Animal Efficacy Rule and will make StatC(TM) available for Government
stockpiling for use in the case of a pandemic.

    About Canopus BioPharma, Inc.:

    Canopus BioPharma, Inc. (OTCPK:CBIA) is dedicated to providing the
safest, most cost effective and efficacious pharmaceutical products and assay
methods in the areas of infectious disease, radiation protection, cancer, and
addiction. With innovative science, proven research and development
leadership, and superior products and compounds, Canopus BioPharma has, since
2001, been committed to becoming a market trend setter in a new era of
healthcare. In addition, the Company is a world leader in the development of
novel camelid antibody products to provide unique avenues of progress and
improvement in assay methods and monitoring capabilities for physicians,
patients and researchers, particularly for food chain protection applications.
Canopus maintains staff in Australia, South Africa, Ireland and the USA.
Additional information on the Company is available at

    Canopus BioPharma Inc Disclaimer:

    With the exception of historical information contained in this press
release, content herein may contain "forward looking statements" that are made
pursuant to the Safe Harbor Provisions of the Private Securities Litigation
Reform Act of 1995. These statements are based on management's current
expectations and are subject to uncertainty and changes in circumstances. In
particular, the Company may not be successful in its efforts commercialize or
attain acceptable clinical results for its products. Investors are cautioned
that forward-looking statements involve risks and uncertainties that could
cause actual results to differ materially from the statements made. These
factors include general economic conditions, delays and risks associated with
the performance of contracts and research and development programs,
uncertainties as a result of research and development, consumer and industry
acceptance, litigation and/or court proceedings, regulatory risks including
approval of Food and Drug Administration filings, the ability to achieve and
maintain revenues and profitability in the Company's business lines, and other
factors discussed in the Company's filings with the Securities and Exchange

For further information:

For further information: Canopus BioPharma Inc Contact: Len Rothstein,
President, Tel. (818) 980-5008, Fax. (818) 980-5088,;
Prof Jiahai Lu, Sun Yat-sen University, Tel. +8620-8733-0605,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890